- ISIN
- US8816242098
- CUSIP
- 881624209
- Sector
- Healthcare
- IPO Date
- Mar 26, 1990
Highlights
- Market Cap
- $37.11B
- Enterprise Value
- $52.89B
- EPS (TTM)
- $1.34
- PE Ratio
- 23.53
- PEG Ratio
- 0.18
- Total Revenue (TTM)
- $17.35B
- Gross Profit (TTM)
- $9.03B
- EBITDA (TTM)
- $3.05B
- Year Range
- $14.99 - $37.35
- Target Price
- $38.33
- ROA (TTM)
- 3.91%
- ROE (TTM)
- 19.00%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TEVA Performance Chart
Teva Pharmaceutical Industries Limited (TEVA) is up 0.9% since the beginning of the year. At $31 per share, TEVA is trading 15.7% below its 52-week high of $37. Investors who bought $1,000 worth of TEVA shares 5 years ago would now be looking at an investment worth $3,111.
Loading charts...
Returns By Period
Teva Pharmaceutical Industries Limited (TEVA) has returned 0.87% so far this year and 84.53% over the past 12 months. Over the last ten years, TEVA has returned -4.49% per year, falling short of the S&P 500 Index benchmark, which averaged 13.67% annually.
Teva Pharmaceutical Industries Limited
- 1D
- -3.32%
- 1M
- -7.60%
- YTD
- 0.87%
- 6M
- 3.83%
- 1Y
- 84.53%
- 3Y*
- 61.02%
- 5Y*
- 25.48%
- 10Y*
- -4.49%
Benchmark (S&P 500 Index)
- 1D
- 1.08%
- 1M
- 2.00%
- YTD
- 9.57%
- 6M
- 10.71%
- 1Y
- 25.41%
- 3Y*
- 19.37%
- 5Y*
- 12.48%
- 10Y*
- 13.67%
TEVA Monthly Returns History
Based on dividend-adjusted daily data since Mar 26, 1990, TEVA's average daily return is +0.07%, while the average monthly return is +1.49%. At this rate, an investment would double in approximately 3.9 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jul 1991 with a return of +42.1%, while the worst month was Aug 2017 at -50.5%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 6 months.
On a daily basis, TEVA closed higher 48% of trading days. The best single day was Jul 27, 2022 with a return of +28.4%, while the worst single day was Aug 3, 2017 at -24.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.20% | -0.65% | -11.05% | 16.43% | 0.71% | -10.87% | 0.87% | ||||||
| 2025 | -19.56% | -7.16% | -6.62% | 0.91% | 8.19% | -0.12% | -7.82% | 18.96% | 9.90% | 1.39% | 31.30% | 16.07% | 41.61% |
| 2024 | 15.90% | 8.68% | 7.30% | -0.43% | 20.50% | -4.02% | 7.26% | 8.26% | -4.50% | 2.33% | -9.00% | 31.35% | 111.11% |
| 2023 | 15.57% | -5.98% | -10.70% | -1.36% | -17.53% | 4.58% | 11.55% | 16.19% | 4.51% | -15.88% | 14.45% | 6.31% | 14.47% |
| 2022 | 5.24% | -3.56% | 15.50% | -7.24% | 4.48% | -17.36% | 24.73% | -3.62% | -10.73% | 10.53% | -1.68% | 3.99% | 13.86% |
| 2021 | 22.07% | -8.66% | 7.25% | -7.28% | -2.80% | -4.81% | -2.53% | -2.38% | 3.40% | -10.27% | -5.61% | -2.91% | -16.99% |
Benchmark Metrics
Teva Pharmaceutical Industries Limited has an annualized alpha of 11.93%, beta of 0.73, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since March 26, 1990.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (69.14%) than losses (46.86%) - typical of diversified or defensive assets.
- R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 11.93%
- Beta
- 0.73
- R²
- 0.12
- Upside Capture
- 69.14%
- Downside Capture
- 46.86%
Return for Risk
Risk / Return Rank
TEVA ranks 90 for risk / return — in the top 90% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TEVA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.14 | ||
| Sortino ratioReturn per unit of downside risk | +0.60 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 1.37 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 3.90 | 2.81 | +1.09 |
| Martin ratioReturn relative to average drawdown | 11.35 | 12.55 | -1.20 |
Dividends
Dividend History
Teva Pharmaceutical Industries Limited provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.74 | $1.16 | $1.16 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.88% | 3.19% | 1.77% |
Monthly Dividends
The table displays the monthly dividend distributions for Teva Pharmaceutical Industries Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Teva Pharmaceutical Industries Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Teva Pharmaceutical Industries Limited was 90.89%, occurring on Aug 15, 2019. The portfolio has not yet recovered.
The current Teva Pharmaceutical Industries Limited drawdown is 53.47%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2019 bear market2019 | -90.89%Aug 2019 | 4y 19d | — | 10y 10moJul 2015 - now |
1998 bear market1998 | -52.14%Jul 1998 | 1y 17d | 1y 5mo | 2y 6moJun 1997 - Dec 1999 |
2011 bear market2011 | -44.12%Sep 2011 | 1y 6mo | 3y 4mo | 4y 10moMar 2010 - Jan 2015 |
1995 bear market1995 | -36.77%Jan 1995 | 10mo 19d | 3mo 3d | 1y 1moFeb 1994 - Apr 1995 |
1996 bear market1996 | -36.50%Aug 1996 | 3mo 1d | 4mo 18d | 7mo 19dMay 1996 - Dec 1996 |
Drawdown Indicators
| TEVA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.89% | -56.78% | -34.11% |
Max Drawdown (1Y)Largest decline over 1 year | -21.79% | -9.10% | -12.69% |
Max Drawdown (3Y)Largest decline over 3 years | -43.70% | -18.90% | -24.80% |
Max Drawdown (5Y)Largest decline over 5 years | -43.70% | -25.43% | -18.27% |
Max Drawdown (10Y)Largest decline over 10 years | -88.41% | -33.92% | -54.49% |
Current DrawdownCurrent decline from peak | -53.47% | -1.43% | -52.04% |
Average DrawdownAverage peak-to-trough decline | -32.01% | -10.71% | -21.30% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.47% | 2.03% | +5.44% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Teva Pharmaceutical Industries Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Teva Pharmaceutical Industries Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for TEVA, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TEVA has a P/E ratio of 23.5. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for TEVA compared to other companies in the Drug Manufacturers - Specialty & Generic industry. TEVA currently has a PEG ratio of 0.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TEVA relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TEVA has a P/S ratio of 2.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TEVA in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TEVA has a P/B value of 4.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TEVA
Add Teva Pharmaceutical Industries Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TEVA